Rheumatic diseases and pregnancy

Current Opinion in Obstetrics and Gynecology

Volumn 22, Issue 6, 2010, Pages 458-465

  Märker Hermann, Elisabeth ^a   Fischer Betz, Rebecca ^b  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

ankylosing spondylitis; antiphospholipid syndrome; drug therapy; pregnancy; rheumatoid arthritis; systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BETAMETHASONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ESTRADIOL; GOLD; HEPARIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEFLUNOMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROGESTERONE; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ANTIPHOSPHOLIPID SYNDROME; CONGENITAL HEART BLOCK; CONTRACEPTION; DISEASE EXACERBATION; FERTILITY; HUMAN; HYPOCOMPLEMENTEMIA; INCIDENCE; KIDNEY DISEASE; LOW DRUG DOSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; SPONDYLITIS, ANKYLOSING;

EID: 78449260858     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e3283404d67     Document Type: Review

References (51)

1. Hench PS. The ameliorating effect of pregnancy on chronic atrophic (in-fectious rheumatoid) arthritis, fibrosis, and intermittent hydarthrosis. Mayo Clin Proc 1938; 13:161-167.
2. Gromnica-Ihle E, Østensen M. Pregnancy in patients with rheumatoid arthritis and inflammatory rheumatic diseases. Z Rheumatol 2006; 65:209-216.
3. Märker-Hermann E, Bauer H, Gromnica-Ihle E. Rheumatic diseases in preg-nancy. Dtsch Med Wochenschr 2008; 133:2410-2414.
4. Østensen M, Förger F, Nelson JL, et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis 2005; 64: 839-844.
5. Kass AS, Lea TE, Torjesen PA, et al. The association of luteinizing hormone andfollicle-stimulating hormonewith cytokinesand markersofdiseaseactivity in rheumatoid arthritis: a case-control study. Scand J Rheumatol 2010; 39:109-117.
6. Guthrie KA, Dugowson CE, Voigt LF, et al. Does pregnancy provide vaccine-like protection against rheumatoid arthritis? Arthritis Rheum 2010; 62:1842-1848.
7. Zrour SH, Boumiza R, Sakly N, et al. The impact of pregnancy on rheumatoid arthritis outcome: the role of maternofet al HLA class II disparity. Joint Bone Spine 2010; 77:36-40.
8. Van de Geijn FE, Wuhrer M, Selman MH, et al. Immunoglobulin G galacto-sylation and sialylation are associated with pregnancy-induced improvement of rheumatoid arthritis and the postpartum flare: results from a large prospective cohort study. Arthritis Res Ther 2009; 11:R193.
9. Förger F, Østensen M. Is IgG galactosylation the relevant factor for preg-nancy-induced remission of rheumatoid arthritis? Arthritis Res Ther 2010; 12:108.
10. Wallenius M, Skomsvoll JF, Irgens LM, et al. Postpartum onset of rheumatoid arthritis and otherchronic arthritides: resultsfrom a patient register linked toa medical birth registry. Ann Rheum Dis 2010; 69:332-336.
11. Chambers CD, Johnson DL, Robinson LK, et al. Organization of Teratology Information Specialists Collaborative Research Group. Birth outcomes in women who havetaken leflunomideduring pregnancy. Arthritis Rheum 2010; 62:1494-1503
12. Østensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive antirheumatic drugs. Rheumatology (Oxford) 2008; 47 (Suppl 3):iii28-iii31.
13. Ali YM, Kuriya B, Orozco C, et al. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010; 37:9-17.
14. Østensen M, Husby G. Ankylosingspondylitisand pregnancy. Rheum Dis Clin North Am 1989; 15: 241-254.
15. Østensen M, Fuhrer L, Mathieu R, et al. A prospective study of pregnant patients with rheumatoid arthritis and ankylosing spondylitis using validated clinical instruments. Ann Rheum Dis 2004; 63: 1212-1217.
16. Förger F, Villiger PM, Østensen M. Pregnancy in patients with ankylosing spondylitis: do regulatoryTcells play a role?Arthritis Rheum 2009; 61:279-283.
17. Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiol-ogy of systemic lupus erythematosus in Europe. Lupus 2009; 18:869-874.
18. Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am 2007; 33:237-252.
19. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United Statesforwomenwithsystemic lupuserythematosusand rheumatoid arthritis. Arthritis Rheum 2006; 54:899-907.
20. Cohen-Solal JF. Hormonal regulation of B-cell function and systemic lupus erythematosus. Lupus 2008; 17:528-532.
21. Smith-Bouvier DL, Divekar AA, Sasidhar M, et al. A role for sex chromosome complement in the female bias in autoimmune disease. J Exp Med 2008; 205:1099-1108.
22. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter's syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 2008; 58:2511-2517.
23. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum 2002; 47:202-209.
24. Ekblom-Kullberg S, Kautiainen H,Alha P, et al. Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol 2009; 38:375-380.
25. Petri M. Sex hormones and systemic lupus erythematosus. Lupus 2008; 17:412-415.
26. Culwell KR, Curtis KM, del Carmen Cravioto M. Safety of contraceptive method use among women with systemic lupus erythematosus: a systematic review. Obstet Gynecol 2009; 114(2Pt 1):341-353.
27. Clowse ME. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheumatol 2010; 24:373-385.
28. Yuen SY, Krizova A, Ouimet JM, Pope JE. Pregnancy outcome in systemic lupuserythematosus (SLE) is improving: resultsfrom acasecontrol studyand literature view. Open Rheumatol J 2008; 2:89-98.
29. Chen CY, Chen YH, Lin HC, et al. Increased risk of adverse pregnancy outcomes for hospitalisation of women with lupus during pregnancy: a nationwide population-based study. Clin Exp Rheumatol 2010; 28:49-55.
30. Clowse ME, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008; 199:127.e1-127.e6.
31. Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with preexisting lupus nephritis: predictors of fet al and maternal outcome. Nephrol Dial Transplant 2009; 2:519-525.
32. Askie LM, Duley L, Henderson-Smart DJ. Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791-1798.
33. Gladman DD, Tandon A, Ibañez D, Urowitz MB. The effect of lupus nephritis on pregnancy outcome and fet al and maternal complications. Rheumatology 2010; 37:754-758.
34. Meroni PL, Tedesco F, Locati M, et al. Antiphospholipid antibody mediated fet al loss: still an open questionfrom a pathogenic pointofview. Lupus 2010; 19:453-456.
35. Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fet al loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006; 33:2214-2221.
36. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol 2010; 115:1256-1262.
37. Laskin CA, Spitzer KA, Clark CA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. J Rheumatol 2009; 36:279-287.
38. Carmona F, Font J, Azulay M, et al. Riskfactorsassociated with fet al losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol 2001; 46:274-279.
39. Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun 2009; 33:92-98.
40. Brucato A, Cimaz R, Caporali R, et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2009. [Epub ahead of print]
41. Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifesta-tions associated with neonatal lupus and maternal/fet al riskfactors. Arthritis Rheum 2009; 60:3091-3097.
42. Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153-1157.
43. Jaeggi E, Laskin C, Hamilton R, et al. The importance of the level of maternal anti-Ro/SSA antibodiesasa prognostic markerofthedevelopmentofcardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55:2778-2784.
44. Rein AJ, Mevorach D, Perles Z, et al. Early diagnosis and treatment of atrioventricular block in the fetus exposed to maternal anti-SSA/Ro-SSB/La antibodies: a prospective, observational, fet al kinetocardiogram-based study. Circulation 2009; 119:1867-1872.
45. Mevorach D, Elchalal U, Rein AJ. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block. Curr Opin Rheumatol 2009; 21:478-482.
46. Friedman DM, Kim MY, Copel JA, et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexame-thasone Evaluation (PRIDE) prospective study. Circulation 2008; 117:485-493.
47. Pisoni CN, Brucato A, Ruffatti A, et al. Failure of intravenous immuno-globulin to prevent congenital heart block: findings of a multicenter, prospective, observational study. Arthritis Rheum 2010; 62:1147-1152.
48. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation offetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: results of a multicenter, prospective, open-label clinical trial. Arthritis Rheum 2010; 62:1138-1146.
49. Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the riskofanti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010. [Epub ahead of print]
50. Ruiz-Irastorza G, Khamashta MA. Managing lupus patients during pregnancy. Best Pract Res Clin Rheumatol 2009; 23:575-582.
51. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69:20-28.